Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06905197 · ClinicalTrials.gov registry record · Phase 1
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 5
- Study locations
NCT06905197 is a Phase 1 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Dizal Pharmaceuticals. The registered enrollment target is 140 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT06905197, a Phase 1 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Dizal Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.
Conditions Studied
Interventions
- DRUG DZD6008
- DRUG Sunvozertinib
Study Locations (5)
New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health - New York
- Herbert Irving Comprehensive Cancer Center - New York
New South Wales
- Blacktown Hospital - Blacktown
- Chris O'Brien Lifehouse - Camperdown
Virginia
- Virginia Cancer Specialist (NEXT Oncology-Virginia) - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06905197
The ClinicalTrials.gov registry entry for NCT06905197 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which DZD6008 is the first listed.
NCT06905197 reports 5 study locations spanning 3 distinct geographic areas - top geographies include New York, New South Wales, Virginia.
Frequently Asked Questions
What is clinical trial NCT06905197 about?
NCT06905197 is a clinical study titled "A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)". This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.
What is the current status of trial NCT06905197?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2025-05-13. Estimated completion is 2028-12.
What conditions does trial NCT06905197 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06905197?
The interventions under investigation include: DZD6008 (DRUG), Sunvozertinib (DRUG).
Who is sponsoring clinical trial NCT06905197?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06905197 being conducted?
This trial has 5 study locations across New York, Virginia, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.